Friday 2 August, 0715 - 0815
|
Strike early and strike strong: LDL-C reduction in very high-risk ASCVD patients.
Speakers: Professor Peter Psaltis and Professor Stephen Nicholls
|
An international perspective on identifying and treating HFpEF
|
Management of Triglyceride-associated Residual Risk in Australia: Practical Implementation of Icosapent Ethyl
Speakers: Adam Nelson, Michael Miller, Dr. Preston Mason, Gemma Figtree
Synopsis: This event will feature an International and Australian panel, discussing the management of high cardiovascular risk patients to ensure optimal outcomes. Despite well-managed LDL cholesterol levels through statins and other novel therapies, elevated triglycerides continue to pose a significant residual risk for atherosclerotic cardiovascular events. Evidence supports the relationship between elevated triglycerides and inflammation, endothelial dysfunction, and an increased risk of heart disease and strokes. In Australia, the management of hyperlipidaemia primarily focuses on lifestyle changes and LDL cholesterol-targeted pharmacological interventions, but there is a need for greater emphasis on identifying patients with elevated triglycerides as a marker of residual risk. Novel treatments such as icosapent ethyl have been approved to reduce cardiovascular risk in patients with elevated triglycerides. This symposium aims to enhance understanding and implementation of lipid management strategies beyond LDL-C management.
|
Potential risk and impact of viral infections in patients with cardiovascular disease.
Speakers: Professor Tim Tan and A/Prof Pravin Hissaria
Synopsis: Viral infections can pose a significant risk for older adult patients with underlying cardiovascular disease. Professor Tim Tan will outline the burden of disease of RSV (respiratory syncytial virus) and shingles in those with underlying CVD, and the potential impact they could have on your patients. A/Prof Pravin Hissaria will then discuss age-related decline in immunity and the role of vaccination in helping to protect your adult patients against vaccine preventable diseases.
|
Breaking Barriers in HFrEF Care: Implementing New Models for Improved Outcomes
Speakers: Dr Gary Gan, A/Professor Kavitha Muthiah
Synopsis: In this meeting, the speakers will:
- Discuss models of heart failure care, including current Australian models of care and clinical trial data
- Present an overview of data supporting use of Entresto as GDMT for HFrEF
- Explore the importance of rapid optimisation of GDMT for HFrEF
- Provide an overview of transplantation and end stage heart failure
|
Why Weight? Transforming weight management with Wegovy® (semaglutide 2.4mg)*
Speakers: Prof Pam Taub and A/Prof Melissa Leung
Chair: Prof Gerald Watts
Synopsis: Obesity can lead to the development of CVD and CVD mortality independently of other cardiovascular risk factors. Hear from a panel of local and international experts including Prof Pam Taub Cardiologist and Professor of Medicine at UC San Diego, alongside A/Prof Melissa Leung & Prof Gerald Watts as they discuss patient cases and share their clinical experience and practical tips on optimising the use of GLP-1RAs in managing overweight or obesity in patients with CVD.
|
VYNDAMAX and ATTR-CM: What Cardiologists need to know.
Speakers: Dr Jay Baumwol
Synopsis: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, life-threatening condition that can often be overlooked as a cause of heart failure. Early diagnosis and treatment are critical for improving outcomes in patients.1
VYNDAMAX® is the first and only approved treatment for ATTR-CM, and it is now PBS reimbursed.2-4 Join our expert panel to hear about the prevalence of ATTR-CM in Australia, the key signs and symptoms to be aware of in suspecting Cardiac Amyloidosis and best practice recommendations in using non-invasive tests to ensure an accurate diagnosis and optimal outcomes for your patients.
References:
- Witteles RM et al. JACC Heart Fail 2019;7:709–16.
- VYNDAMAX Product Information.
- Pharmaceutical Benefits Scheme (www.pbs.gov.au).
- Therapeutic Goods Administration - https://www.tga.gov.au/search?keywords=ATTR-CM&submit=Search.
|
